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Abstract

Low plasma HDL cholesterol (HDL-c) has been recognized as a biomarker of
cardiovascular disease (CVD) and diabetes. Also, low HDL-c is one of the characteristics of
metabolic syndrome (MetS).
Objective: To assess whether low HDL-c and/or low HDL functionality are associated
with higher risk for CVD in subjects classified with MetS.
Methods: Forty-subjects with MetS (11 men /29 women, 52.4 ± 9.5 years participated in
the study. Anthropometric data [weight, height, BMI, waist circumference (WC), blood pressure
(BP)], fasting plasma biomarkers [lipids, glucose, liver enzymes: alanine aminotransferase (ALT),
and aspartate aminotransferase (AST), plasma insulin, and glycosylated hemoglobin (HbA1c)],
biomarkers of oxidative stress and inflammation, and biomarkers of antioxidants status
[glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, and total antioxidant
capacity (TAC)] were measured. Lipoproteins particles were measured to identify the size and
number. Also, the functionality of HDL was further assessed by measuring plasma
apolipoproteins, paraoxonase-1(PON-1) and serum amyloid A1 (SAA1).
Results: Participants had a mean BMI of 32.3 ± 2.7 kg/m2 (29.8 – 39.3 kg/m2) placing the
majority in the obesity category. In terms of MetS characteristics, all subjects (100%) fit the criteria
for WC; 63% either had high systolic BP, high diastolic BP, or both; 70% were hyperglycemic;
48% had elevated plasma triglycerides (TG), and 43% had low HDL-c. We divided the subjects
into two categories, Low HDL-c (men < 40 mg/dL and women < 50 mg/dL) (n = 17) and Normal
HDL-c (men ≥ 40 mg/dL and women ≥ 50 mg/dL) (n = 23). Those with Low HDL-c had higher

xii

systolic BP (129.9 ± 9.7 vs 121.2 ± 14.2 mm Hg, p < 0.05), higher TG (166.6 ± 8.0 vs 115.5 ±
56.8 mg/dl, p < 0.05), and lower TAC (1.23 ± 0.9 vs 2.09 ± 1.5 mM Trolox equivalents, p < 0.05).
In addition, strong negative correlations were found between HDL-c concentrations and each of
the following parameters: WC (r= - 0.418, p < 0.01), insulin (r=-0.413, p < 0.05) and ALT (r = 0.324, p < 0.05). Lipoprotein data showed that large VLDL, medium VLDL, and small LDL
particles were significantly higher in the Low HDL-c group (9.4 ± 6 vs 5.6 ± 4.4 nmol/L, p < 0.05),
(25.1 ± 11.3 vs 15.8 ± 8.2 nmol/L, p < 0.01), (822.5 ± 283 vs 522.4 ± 288.2 nmol/L, p < 0.01),
respectively. Both large and total HDL particles were higher in the Normal HDL-c group (8.2 ±
4.1 vs 4.3 ± 1.9 µmol/L, p < 0.01), (37.5 ± 4.4 vs 30.8 ± 4.8 µmol/L, p < 0.01), respectively. Apo
A-I was significantly higher in Normal HDL-c group (985.4 ± 274.2 vs 790.7 ± 188.1 mg/L, p <
0.05). Also, Apo A-I was positively correlated with total HDL (r = 0.671, p < 0.01) and large HDL
particles (r = 0.530, p < 0.01), respectively. PON-1 activity was significantly higher in the Normal
HDL-c group (26.7 ± 14.1 vs 12.4 ± 16.1 U/ml, p< 0.05).
Conclusion: These data suggest that in these men and women with MetS, measuring both
HDL-c concentrations and HDL particles can provide important information about levels and
functionality of the protective HDL. In regards to plasma HDL-c, subjects with Low HDL-c
appeared to have higher risk for CVD including dyslipidemia, hypertension, and higher
concentrations for more atherogenic lipoproteins. Further, TAC, Apo A-I and PON-1 activity were
lower among this group. These results confirm that individuals with Low HDL-c and MetS have
increased risk for CVD.
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Chapter 1
Introduction

Cardiovascular disease (CVD) is estimated to be the major cause of death with an
estimate of 31% deaths per year globally.1 CVD is a health concern that can occur by different
modifiable risk factors including tobacco smoking, dyslipidemia, hypertension, and obesity. When
there is an intake of excess energy coupled with physical inactivity, an epidemic of obesity
increases affecting optimal health. Another health issue correlated with obesity that increases the
risk factors of CVD is metabolic syndrome (MetS). In the United States, it has been estimated that
nearly 35% of adults have MetS 2. This metabolic abnormality is defined by having three or more
of these clinical parameters; central adiposity, high blood pressure, hyperglycemia, high plasma
triglycerides (TG), and low HDL-cholesterol (HDL-c) concentrations 3. Another factor that can
contribute to an increase of CVD risk is the high concentrations of LDL-cholesterol (LDL-c)
4

.These abnormalities can further increase an individual’s risk for both CVD and type II diabetes

mellitus 5. Plasma low HDL-c as one of MetS criteria has been shown to have an inverse
relationship with the risk for coronary heart disease (CHD), even at low LDL-c levels, below 70
mg/dL 6. Observational studies have been estimated that for each increment of 1 mg/dL in HDLc, there is an approximate 2–3% reduction in CVD risk7,8. This relationship is thought to be due to
the cardioprotective properties of HDL. The most known function of HDL is that it mediates efflux
of cholesterol ester (CE) from peripheral cells and transfers the excess CE to the liver for excretion
9

, in a process called reverse cholesterol transport (RCT). Other cardioprotective properties of HDL

are: 1) inhibition of the expression of endothelial adhesion molecules and its action as antiinflammatory agent; 2) antioxidative effects due to the association of HDL with several antioxidant
1

enzymes such as paraoxonase-1 (PON-1), glutathione peroxidase (GPx), and superoxide dismutase
(SOD); 3) prevention of oxidized LDL (Ox-LDL) induced apoptosis; and 4) regulation of platelet
adhesion10,11. The HDL particle has two main key properties, the first one is its ability to bind to
receptors on both hepatic and non-hepatic cells such as; ATP-binding cassette transporter A1
(ABCA1) and scavenger receptor B1 (SR-B1)12,13. Another key property is enhancing the
responsible enzyme for esterification of free cholesterol to CE through apoA-1 components, which
is known as plasma lecithin-cholesterol acyltransferase (LCAT) activity

14

. HDL particles are

highly heterogeneous in size, shape, density, cholesterol, phospholipids as well as apolipoproteins
content11,15,16. Usually, in clinical settings, plasma HDL-c concentrations are measured as a
predictor and an independent risk parameter for CVD16–18. In contrast, recent data suggest that
even with high HDL-c concentrations, the incidence of atherosclerosis is not reduced 17, and very
large HDL particles may induce the cardioprotective properties of the functional HDL

18

.

Interestingly, in two large trials in high-risk groups, it was shown that the occurrence of cardiac
events was significantly and inversely associated with raised HDL particle numbers but not plasma
HDL-c concentrations
around 50%

20

19

, and high HDL particle numbers significantly reduced CHD death by

. Therefore, measuring both the HDL-c concentrations as well as parameters for

HDL functionality in high-risk populations such as individuals with MetS is of great of interest.
The aim of the present study was to analyze whether HDL-c and/or HDL functionality are
associated with additional biomarkers of CVD in subjects classified with MetS. For that, we
hypothesized that subjects with MetS with low HDL-c will have a greater risk for CVD as
determined by clinical biomarkers, than subjects with MetS and normal HDL-c.

2

Chapter 2
Review of Literature

2.1 Cardiovascular Disease
Worldwide, the prevalence of obesity nearly doubled between 1980 and 2008 with
cardiovascular disease (CVD) remaining the second leading cause of death globally1. As reported,
obese individuals have 3.5 times higher probability of having 3 risk factors for CVD and 2.4 times
higher possibility of elevated plasma cholesterol1. There are an estimated 62 million individuals
diagnosed with CVD in the U.S.21,22. It was estimated that 75% of patients with heart failure had
a history of hypertension23. As reported, the exact cause of CVD is unknown but there are wellknown factors that increase the risk of CVD24. CVD risk factors can be categorized into two
groups, nonmodifiable and modifiable risk factors. The nonmodifiable risk factors include those
that we cannot control, such as age, gender, ethnicity, and family history. In contrast, the
modifiable risk factors are those that we can control and manage, such as dietary intake, weight,
abdominal obesity, smoking, high blood pressure (BP), and type 2 diabetes mellitus (T2D).
Abdominal obesity is one of the CVD risk factors and also a biomarker of metabolic syndrome
(MetS) that can be measured by calculating waist circumference (WC) and waist-to-hip ratio
(WHR). The increase of visceral adipose tissue can promote insulin resistance, hypertension, and
dyslipidemia25,26. As reported, after adjusting for age, each 1 cm increase in WC and 0.01 increase
in WHR is associated with an increase of 2% and 5% respectively, of CVD27. In the Framingham
Heart Study, 5,881 participants were followed up to evaluate the relationship between body mass
index (BMI) and the incidence of heart failure28. Heart failure developed in 496 participants within
14 years follow up, and data showed that the incidence of heart failure increased with the increase
3

of BMI in both genders28. It was reported that for each increment increase of 1unit in BMI, the
risk of heart failure was increased in men and women about 5% and 7%, respectively28.
Hypertension is another risk factor of CVD and one of the MetS features. In the U.S., it was
estimated that approximately 50 million individuals have hypertension21. The prevalence of
hypertension and T2D was also increased with the increase of BMI28. Low plasma high-density
lipoprotein cholesterol (HDL-c) level is an important risk factor of CVD as well as a MetS
biomarker. Studies have been shown that low HDL-c concentrations are associated with increased
mortality29,30. High levels of oxidized low-density lipoprotein (Ox-LDL ) and lipoprotein a [Lp
(a)] are abnormal lipoprotein profiles associated with CVD in MetS31. It has been observed that
obese individuals who met MetS criteria have higher levels of oxidative stress and inflammatory
markers including tumor necrosis factor- (TNF-), interleukin 8 (IL-8), and C-reactive protein
(CRP) than those without MetS 32.
2.2 Metabolic Syndrome
Metabolic syndrome is a condition with a combination of metabolic disorders that increases
the risk of CVD. This condition leads to increasing the risk of heart disease by 2-fold and T2D by
5-fold5. The prevalence of this disorder is increasing, and it was estimated to be 25% worldwide33.
Different factors can contribute to the development of MetS such as excess body weight, physical
inactivity, rich fat and carbohydrate diets that can contribute to central obesity and insulin
resistance (IR)33. Young individuals with MetS can suffer from serious health complications in
their later years, thus controlling this condition and reducing its prevalence should be the main
goal. Weight loss, exercise and healthy diet seem to have the biggest effect on health and help to
reduce MetS parameters. A common feature for MetS subjects is the excess body fat (especially
visceral fat), studies have been shown that fat accumulated in the visceral area was associated with
4

hypertension, T2D, and atherogenic dyslipidemia26,34. Atherogenic dyslipidemia is characterized
by increased triglycerides (TG) and low HDL-c. These abnormalities can accelerate the risk of
CVD, especially in a high-risk group as MetS.
2.2.1 Definition
In history, the term (metabolic syndrome) is a debated topic. In 1975, a German researcher,
Hermann Haller coined this term35. Also, in 1988, Gerald M Reaven described a phenomenon that
occurs in individuals with coronary artery disease (CAD) that includes a combination of the
following; IR, hyperglycemia, hyperinsulinism, hypertriglyceridemia, hypertension, and low
plasma concentration of HDL-c, as Syndrome X. After that the interest to identify this
phenomenon increased36. There were different criteria set out by different associations to define
and diagnose this condition. The World Health Organization (WHO) was the first to define MetS
criteria in 1988, as a presence of high insulin levels in addition to two of the following factors:
abdominal obesity, hypertriglyceridemia and low HDL-c; hypertension, or microalbuminuria. In
1999, the European Group for the Study of Insulin Resistance (EGIR) suggested that the term
insulin resistance syndrome was more appropriate and modified MetS criteria to have high fasting
insulin concentrations plus two other factors out of four: abdominal obesity; high TG and low
HDL-c; high BP; or high fasting plasma glucose levels33. The cutoff of these factors was different
than those used by WHO. Another association set a criterion of MetS and became the most
common guidelines was the National Cholesterol Education Program –Third Adult Treatment
Panel III (NCEP:ATP III) in 2001, and defined MetS as the having three of the five clinical
measurements which include high WC, high BP, high fasting glucose, hypertriglyceridemia, and
low HDL-c3.
2.2.2 Parameters of MetS
5

According to NCEP: ATP III guidelines, there are five metabolic disorders and the
presence of three of these features, will meet the definition of MetS. Abdominal obesity has a
greater impact on health and can increase CVD risk factors37,38. Abdominal obesity as WC has
cutoffs that are different based on gender. For males, WC must be equal to or greater than 102 cm
(40 inches) to meet the guidelines. For females to meet WC criterion, it must be equal to or greater
than 88 cm (35 inches). Dyslipidemia is characterized by higher TG and lower HDL-c
concentrations. Greater than or equal to 150 mg/dL is considered to be high TG. The cutoff of
HDL-c concentrations is also based on gender. Less than 40 mg/dL (1.0 mmol/L) for males is
considered low HDL-c concentrations. For females, the cut-off point of HDL-c is less than 50
mg/dL (1.3 mmol/L). Another clinical measurement, common among obese individuals with IR is
high BP. The guidelines defined that having the systolic BP equal to or over 130 mm Hg and the
diastolic BP equal to or over 85 mm Hg is a criterion of MetS. Obesity itself causes and aggravates
IR which is linked to several CVD risk factors, such as hyperglycemia and T2D33. High fasting
glucose or in another term hyperglycemia is common among obese individuals when insulin in the
body cannot regulate glucose levels after a meal intake. Thus, this can lead to elevated plasma
glucose remaining in circulation. The cutoff of fasting plasma glucose was modified in 2004 from
greater than or equal to 110 mg/dL (6.1 mmol/L) to greater than or equal to 100 mg/dL (5.6
mmol/L), in accordance with the American Diabetes Association’s updated standard of normal
fasting glucose level39.
2.2.3 Prevalence of Risk Factors
According to the National Health and Nutrition Examination Survey (NHANES) 2003–
2006 and NCEP:ATP III guidelines, the most prevalent of MetS criteria were central obesity
(53%), hypertension (40%), and hyperglycemia (39%), and the least prevalent were
6

hypertriglyceridemia (31%) and low HDL-c (25%)40. There were differences in the prevalence of
MetS risk factors by gender. As reported, males had a higher age-adjusted prevalence of
hypertension, hyperglycemia, and hypertriglyceridemia whereas females had a higher ageadjusted prevalence of central obesity and low HDL-c concentrations40. It seems that among
females the prevalence of each risk factors was increased with age. For males, the prevalence of
hypertension and hyperglycemia was increased with age, but for central obesity,
hypertriglyceridemia, and HDL-c were no significant differences with age40.
Based on race and ethnicity, the age-adjusted patterns varied between groups. Among
males,

non-Hispanic

whites

and

Mexican-Americans

had

a

higher

prevalence

of

hypertriglyceridemia and low HDL-c than non-Hispanic blacks40. Non-Hispanic white males had
a higher prevalence of central obesity than non-Hispanic black males, but non-Hispanic blacks had
a higher prevalence of hypertension than Mexican Americans40. For females, central obesity and
hyperglycemia were more common among non-Hispanic blacks and Mexican Americans than nonHispanic whites40. Non-Hispanic blacks had the highest prevalence of hypertension, while
Mexican Americans had the highest prevalence of low HDL-c and hypertrigleyceriemia40.
When BMI increased, the prevalence of each of the five risk factors as well as the
prevalence of MetS was increased for both genders40. Overweight males were more than 6 times
and obese males were more than nearly 32 times as likely to meet MetS criteria than males with
normal weight or underweight40. Among females, overweight was 5.5 times and obese was 17
times more likely to meet this criterion than normal and underweight40. It was reported that
between 2003–2004 and 2013–2014, there were no significant changes in childhood obesity
prevalence, but among adults there was an increasing trend41.

7

As reported, males and females 40–59 years old were around three times more likely to
meet MetS criteria than those of younger age40. 25% of non-Hispanic black males met the ATPIII
criteria compared to 37% of non-Hispanic whites40. In contrast, both non-Hispanic black and
Mexican American females were about 1.5 times more likely to meet MetS criteria than nonHispanic white40.
2.3 Lipoproteins Overview
Lipoproteins are clusters of lipids associated with proteins and serve as transport vehicles
for lipids in the lymph and blood. Typical lipoproteins consist of hydrophobic molecules with TG
and cholesterols on the inside surrounded by hydrophilic phospholipids (PL) on the outside. The
plasma lipoproteins have major classes defined by density and size at which they are isolated.
Chylomicron (CM), very low-density lipoprotein (VLDL), and there is the intermediate density
lipoprotein (IDL), which is the transit form of VLDL conversion to low density lipoprotein (LDL),
and there is HDL42.
After dietary fat intake, CM are produced and secreted by the enterocytes into the lymph,
and they require apo B-48. These chylomicrons are TG-rich particles with around 82% TG. In
addition, CM have, cholesteryl esters (CE), PL, vitamins A and E in the core and a monolayer of
PL, free cholesterol, and protein on the surface43. CM also have apo E, apo C-II and apo C-III that
were acquired from HDL in circulation. After the action of the enzyme lipoprotein lipase (LPL),
the CM particles become smaller and returns to the liver as chylomicron remnant43. Typically, CM
density is 0.92 - 0.96 g/ml with diameter approximately 100-500 nm42.
VLDL particles are made primarily in the liver and they require apo B-100 for secretion.
Around half is TG, and they also have apo A-I, apo A-II, apo E, apo C-I, apo C-II, and apo C-III43.
VLDL particle density is 0.95- 1.006 g/ml and about 30-80 nm in diameter42. During VLDL
8

circulation, TG is donated to extra-hepatic tissues by the action of LPL43. As the TG is removed
from VLDL, IDL is formed and then converted to LDL43. IDL particle density is heavier than
VLDL with about 1.019 g/ml and 25-50 nm in diameter42. High concentrations of plasma IDL are
associated with increased risk of CVD44.
LDL is known as a cholesterol rich lipoprotein that contains only apo-B100, and can be
removed by LDL receptor on the liver and extra-hepatic tissues43. LDL particle density is about
1.029-1.063 g/ml and has different subclasses42. Elevated plasma LDL-c is a risk factor for the
development of CVD31. LDL-c is positively correlated with CAD and CVD mortality in the
presence of MetS condition20. The heaviest lipoprotein and the smallest one is HDL, which will
be discussed below in more detail.
2.3.1 HDL Composition and RCT
As mentioned above, HDL has the highest density with 1.063- 1.210 g/ml, and the smallest
size (15-20 nm). HDL can originate from both the liver and intestine as a nascent particle devoid
of lipids but containing apo A-I. Discoidal HDL particles interact with ATP-binding cassette
transporter A1 (ABCA1), which is located at peripheral tissues, then free cholesterol will be
esterified by the action of the enzyme lecithin cholesterol acyltransferase (LCAT) to form the
spherical −HDL. LCAT is activated by the major apolipoprotein in HDL, apo A-I13. Half of each
HDL particle is composed of PL, unesterified cholesterol, TG and exchangeable apolipoproteins
such as, apo A-I, apo A-II, apo E, apo C-I, apo C-II, and apo C-III43. The other half consists of
proteins, and according to the proteomic studies, they discovered that more than 100 proteins are
in HDL particles in addition to the apo As45. HDL particles play a critical role in transporting the
excess cholesterol from the peripheral tissues to the liver for elimination46. This beneficial process
is known as reverse cholesterol transport (RCT). RCT is inversely correlated with CVD in that it
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plays an important role in modifying the formation and development of fatty plaques47. There are
different HDL subclasses, nascent HDL, HDL2 (larger and less dense), and HDL3 (smaller and
denser). Nascent HDL known as pre- HDL has low lipid content while -HDL (HDL2+HDL3)
has high lipid content48.
RCT occur in three stages; extravascular, intravascular, and intrahepatic46. The first stage
is cholesterol efflux from cell membranes and it is transported between cell membranes via the
action of ABCA1, which is located on extra-hepatic tissues and generates structures that facilitate
the interaction with lipoproteins. Thus, the HDL particles uptake the unesterified cholesterol as
well as antioxidant substances such as, vitamin E, Lutein and Zeaxanthin via the action of apo AI in HDL particles and ABCA-1 on the intestine9. The second stage is the esterification of free
cholesterol in HDL by the action of the enzyme LCAT, and some of the formed CE is transferred
to CM and VLDL by cholesteryl ester transfer protein (CETP) while some will remain in the HDL
core to increase its size and decrease the density9,46. HDL particles are taken up by the liver through
two pathways. The direct pathway is through apo A-I, which is a ligand for hepatic scavenger
receptor BI (SR-BI) where selective lipid uptake occurs, then the cholesterol is directed for biliary
excretion. The indirect pathway is through hepatic LDL- receptor, and by the action of CETP,
which facilitates the exchange of TG from the apo B containing lipoproteins (VLDL, LDL, CM)
with CE from HDL9,43. The RCT is finalized by the biliary excretion46.
2.3.2 HDL Health Benefits

In addition to removing excess plaque lipids through the RCT process, HDL exhibits antiinflammatory properties through interactions with the vascular endothelium and circulating
inflammatory cells43,49. HDL has antithrombotic and antioxidant properties and improves
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endothelial function, as well as expression of inflammatory mediators43. HDL particles have an
important capacity to carry antioxidants47. Abnormal HDL particles promote endothelial
superoxide production and reduce nitric oxide (NO) bioavailability, thus, causing endothelial
dysfunction, increasing BP and increasing cellular inflammation50. In contrast, normal HDL
particles have favorable effects on endothelial cell proliferation, and promote NO production49.
Also, it has been shown that HDL has antiapoptotic functions for a number of cell types
such as, smooth muscle cells, some leukocytes, pancreatic β cells, cardiomyocytes, and boneforming cells

43,49

. Recent studies in humans suggest that HDL-c was inversely associated with

CVD30,50. The Framingham Heart Study identified CVD risk factors such as low plasma HDL-c
concentrations, which were associated with a higher mortality rate29. It has been estimated that for
each increment of 1 mg/dL in HDL-c, the CHD risk is reduced by 2% - 3% in men and women,
respectively7. In a 10-year prospective study of male employees, it was reported that the
development of ischemic heart disease was significantly higher among males with low HDL2, and
high levels of LDL, IDL, and small VLDL51.
Despite previously mentioned HDL benefits, HDL particles can be modified to become
dysfunctional and pro-atherogenic particles under certain conditions such as, obesity, MetS, and
chronic inflammation30,52,53. HDL is considered an anti-atherogenic lipoprotein, but HDL levels in
unhealthy individuals is sometimes less efficient. Obesity and MetS affect HDL particles and
cholesterol, HDL become smaller in size and less dense, which will impair its anti-atherogenic and
anti-inflammatory properties54,55. All the three HDL subclasses are involved in RCT. However,
there were negative correlations between HDL2 (larger) and CVD31,46. In addition, it has been
suggested that HDL3 particles (smaller) may have greater protective effects than the larger
particles56. This topic remains controversial.
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2.3.3 HDL particles and HDL-c Measurements
It is well known that plasma HDL-c concentrations are negatively associated with
atherosclerotic CVD, especially CAD. HDL-c can be measured in plasma and serum. Previous
clinical trials that aimed to raise HDL-c by pharmacology drugs including fibrates, niacin, and
CETP inhibitors have failed to show health benefits or to improve CVD biomarkers and reduce
CVD mortality 57,58. However, previous studies indicate that HDL particles concentrations can be
superior to HDL-c concentrations as a predictor of CVD59. Measurements of HDL particle number
and size become an improved assessment of cardiovascular risk6. HDL constitutes a heterogeneous
group of particles that differ in density, size, lipid composition, and apolipoprotein content, thus
HDL can be fractionated into discrete subclasses by different techniques12. HDL separation can be
done by charge as capillary isotachophoresis60, and HDL size by using one of the following: gel
gradient

electrophoresis

separation61,

Fast

liquid

chromatography,

Ion

exchange

chromatography62, or Nuclear magnetic resonance (NMR) by proton spectroscopy. Gradient gel
electrophoresis can separate HDL into two fractions on the basis of density, HDL2 (1.063-1.125
g/ml) and HDL3(1.125-1.21 g/ml)12. These particles can be further divided into sub-fractions,
HDL2 into HDL2b (10.6 nm) and HDL2a (9.2 nm), and HDL3 into HDL3a (8.4 nm), HDL3b (8.0 nm),
and HDL3c (7.6 nm)12. NMR is a technique that quantifies the number and size of VLDL, IDL,
LDL, HDL particles and expresses each as lipoprotein particle concentration and as an average
particle size63. It quantifies more than 30 lipoprotein fractions that can be grouped into 10
subclasses based on diameter: large VLDL (> 60 nm), medium VLDL (35–60 nm), small VLDL
(27–35 nm), IDL (23–27 nm), large LDL (21.2–23 nm), medium LDL (19.8–21.2 nm), small LDL
(18–19.8 nm), large HDL (8.8–13 nm), medium HDL (8.2–8.8 nm) and small HDL (7.3–
8.2 nm)63.
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Methods for measurement of HDL sub-fractions as mentioned before and measuring HDL
functionality may also be more effective in predicting CVD risk than measuring plasma HDL-c
concentrations alone. It is suggested that future research should determine the remodeling of HDL
particles in unhealthy conditions50. Obesity and MetS are conditions that alter HDL particles and
reduce HDL-c concentrations64. There is evidence that the small HDL particles mostly seen in
MetS are functionally defective56. Further, small HDL particles were observed along with CVD63.
In contrast, large HDL particles are strongly inversely associated with CVD63. Among MetS,
abnormalities of lipoproteins particles were observed64. However, the relationship between sizes
and numbers of HDL particles and the MetS parameters have not been fully addressed.
2.3.4 HDL Functionality
During tissue injury, inflammation status will induce the acute phase in which the liver
increases the synthesis of acute-phase protein, which is serum amyloid A (SAA) and its isoforms,
1 and 214. It is known that proinflammatory cytokines including interleukin 1- (IL-1), interleukin
6 (IL-6) and TNF- play important roles in hepatic expression of SAA response to acute-phase65.
Elevation of plasma SAA levels causes mainly HDL3 remodeling, by which SAA displaces apo
A-I to become an apolipoprotein of HDL and may alter HDL metabolism and cholesterol
transport14. SAA may also promote a pro-inflammatory and pro-atherogenic HDL through limiting
its ability to promote RCT66. Another important marker that significantly associates with CHD and
has impaired the antiatherogenic properties of HDL particles is apo C-III. These findings are based
on an observational study, which analyzed HDL-apo C-III levels in patients with and without
CHD67. Patients with CHD were on statin treatment. After adjusting of covariates, among CHD
patients with statin, plasma HDL along with elevated plasma apo C-III, and even with elevation
of HDL-c concentrations, there was remaining CVD risk among CHD patients67. Thus, SAA1 and
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apo C-III are considered markers for dysfunctional HDL particles. In contrast, apo A-I, apo-E and
Paraoxonase-1 (PON-1) are markers for functional HDL particles. Apo A-I is one of the major
HDL apolipoproteins that is required for normal HDL biosynthesis. Higher levels of HDL-c have
been shown to significantly reduce CVD risk and in particular higher levels of apo A-I were
negatively associated with CVD risk16. PON-1 is an enzyme that is synthesized mainly in the liver
and secreted into the blood where it associates with HDL particles68. PON-1 has atheroprotective
effects including inhibition of excess cholesterol synthesis and promotion of cholesterol efflux.
PON-1 has also, anti-inflammatory functions and raises antioxidant effects of HDL68.
Paraoxonase-1, 2, and 3 have antiatherogenic properties including delayed pro-atherogenic
oxidation of LDL and cell membranes to prevent atherosclerosis development69. It was reported
that due to lower PON-1 activity the interaction with SR-B1 receptors was less efficient among
CHD patients when compared it with healthy individuals70. Thus, HDL associated PON-1 protects
against CVD through previously described mechanisms of the action of PON-1.
2.4 Therapeutics
The primary goal of caring for individuals with MetS is to reduce the clinical
atherosclerosis disease risk factors. First-line therapy should focus on the major risk factors, such
as elevated LDL-c, reduced functional HDL-c, hypertension, and prediabetes. Individuals with
MetS rarely have normal body weight and are physically active. Therefore, lifestyle modifications
including decreases in body weight, increases in physical activity, or following anti-atherogenic
diets could be the key emphasis in MetS management. According to the American Heart
Association, the first line of therapy should be a healthy diet and increased physical activity to
achieve weight loss71. Studies have shown an improvement in serum cholesterol, TG, HDL-c,
inflammatory markers, BP and IR72–74. In the last 50 years, studies have been focused on examining
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the relationship between health and diet. Many studies assessed the role of different diets on health
benefits and decreases in the risk for disease75.
2.4.1 Energy-Restricted Diets
Energy-restricted diets are the most common dietary strategies for reducing excess weight
and related comorbidities. There is a variety of options for planning and monitoring a reduced
kilocalorie diet. While some strategies recommend energy reduction without restricted food types,
others are using the exchange systems to plan energy and nutrient intake42. The exchange system
that has the flexibility to choose the daily amounts of calories from an exchange list of foods was
established by American Diabetes and American Dietetics Associations76. The main approach of
choosing a weight management plan is to be based on nutrition and exercise principles, suitable
for each individual based on their preferences to promote long-term lifestyle changes to reduce
weight effectively and to teach meal planning skills 76. The common problem in weight loss plans
is helping the individual to maintain the weight loss long-term, rather than follow hypocaloric diets
for a specific period of time, and face the difficulties to follow the new dietary habits. For
individuals who are overweight or obese, which is the case for most individuals with MetS, weight
loss is an urgent step as it is associated with the improvement of the individual metabolic profile
of MetS. Weight loss is associated with improvement of visceral obesity, high blood pressure, and
high fasting glucose77.
Further, weight loss can also improve the low-grade inflammation condition among
individuals with MetS78. At the same time, body weight reduction is associated with the
improvement in plasma glucose levels and IR. In studies done with diabetic overweight/obese
subjects [The Look AHEAD (Action for Health in Diabetes), n= 5,145] have shown that 5-10%
loss of body weight can improve participant’s fitness level, reduce glycosylated hemoglobin
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(HbA1c), and improve CVD risk factors, such as decreasing high BP, decreasing fasting glucose
levels, increasing plasma HDL-c, decreasing LDL-c, and decreasing TG concentartions79. Also,
there was an evidence that even small weight reduction (5-10%) can reduce CVD risk factors, and
the guidelines recommend a 5-10% loss of weight as an initial goal to obtain health benefits80,81.
2.4.2 Moderate/Low Carbohydrate Diet
The Food and Nutrition Board, Institute of Medicine, and National Academies
recommendations set an Acceptable Macronutrient Distribution Ranges for 18+ years old daily
intake for both genders, the percentages range are 45–65, 10–35, 20–35 for carbohydrate (CHO),
protein, and fat respectively. The amount vs quality of CHO intake is a controversial topic, some
studies suggested that the CHO reduction has health benefits especially with great weight loss and
improved lipid profile82–84, while others suggested that the quality of CHO as measuring with
glycemic index (GI) is more important as the quantity. GI is a method that consists of a ranking
on a scale from 0 to 100 for classifying CHO-containing foods according to the postprandial
glucose response42. The consumption of high GI-CHO has been associated with hyperglycemia,
IR, T2D, and hypertriglyceridemia85,86. These abnormalities are directly related to MetS.
Moderate, low CHO diets are different on their CHO percentages, for moderate the CHO
distribution can be around 40 to 55% of daily energy requirement. In two studies done with T2D
subjects, moderate CHO intake (40%) has shown health benefits83,87. Low CHO intake can reach
5-30% energy from CHO. Consumption of low CHO diets has shown benefits to decrease plasma
TG, decrease small LDL, decrease inflammatory markers, and increase HDL-c. In addition, it has
a role in reducing blood pressure and increasing weight loss88. When total fat is reduced, CHO
intake is increased and healthy unsaturated fats are decreased 89. Although consumption of low-fat
diets was associated with significant weight loss, CVD rates did not decrease89. After comparing
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these two diets, it seems that low CHO diet had further health benefits for increasing HDL-c
significantly with a decrease in phenotype B of LDL, which is the small dense LDL particles that
are considered more atherogenic with high susceptibility to become oxidized due to short lag phase
and greater concentrations of conjugated dienes76,90.
In one study, researchers examined the effect of approximately 10% CHO daily intake on
weight loss and MetS parameters. Their participants checked their ketone levels through urine tests
for maintaining ketones production after following the carbohydrate-restricted diet (CRD)91. In
contrast, high CHO intake has been linked with an increase in MetS numbers regardless of fat
intake in males and with higher MetS risk among females that consumed high CHO and low fat24.
For Asian subjects with MetS who had relatively low BMI and consumed low-fat diet and high
CHO intake, the incidence of MetS and CVD was higher than in western countries92. These results
may indicate that excess CHO intake, not fat intake is associated with MetS. In another study,
subjects consumed 13% of carbohydrates for 12 weeks, and researchers observed a significant
reduction in plasma lipoprotein (a) and a reduction in CRP and TNF-α, which are inflammatory
markers93. These findings are important because they add to the benefits of CRD in lowering
inflammatory markers and plasma cholesterol. In subjects with MetS, a study was conducted to
compare between consumption of CRD (20-25% CHO) and consumption of the American Heart
Association diet (50-55% CHO)73. The CRD group had large VLDL particles while medium and
small LDL particles were decreased73. In addition, apo B levels were significantly decreased73.
Many studies concluded that a reduced carbohydrate diet results in a spontaneous reduction in
energy intake that may lead to weight and fat loss94. Although CHO restricted diets are high in fat,
the absolute amount of total fat is usually unchanged; and it has been shown that the only nutrient
that is increased or maintained is protein24,95,96.

17

2.4.3 Daily Egg Consumption

Egg consumption is one of the dietary strategies that has been associated with changes in
small LDL and HDL subclasses to a larger one, and that has a positive effect on reducing CVD
biomarkers

64

. Participants with MetS have followed CRD along with consumption of 3 whole

eggs/day for 12 weeks, large VLDL, small LDL-c, small IDL lipoproteins and insulin resistance
were improved, and HDL numbers and sizes were increased 64. Large VLDL carries more TG, and
smaller LDL and IDL are prone to be easily oxidized. Whereas larger HDL is favorable because
of their roles in the RCT. Also, intake up to 3 eggs/day showed an improvement in HDL-c in
healthy subjects 97. For individuals with MetS, intake of 3 eggs/day along with CRD had benefits
on lipid profile and were safe to consume

64

. Egg contents that might have role in influencing

HDL-c concentrations are phosphatidylcholine and dietary cholesterol98. Dietary phospholipid
intake has been associated with the increase of HDL-c concentrations in human and animal
studies99. Egg consumption also had a role in RCT, in which the serum cholesterol efflux capacity
was increased in subjects with MetS98. Studies have shown that with egg intake, HDL particles
and cholesterol levels were positively improved in healthy populations100,101 as well as in MetS64.
These findings indicate that eggs may be considered as a functional food that can promote
beneficial shifts in HDL composition, metabolism, and function in both healthy and MetS
populations.

Eggs contain carotenoids lutein and zeaxanthin, antioxidants that may protect against lipid
oxidation102. In a study conducted in healthy populations, the consumption of 0, 1, 2, 3 eggs per
day were evaluated101. Compared to no egg intake with the 1-3 eggs/day, large LDL and large
HDL were increased101. Large particles of LDL are known to be the least atherogenic LDL
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subfraction because they are less susceptible to modification and oxidation. Also, apo A-I and
LCAT were increased with 1-3 eggs/day consumption while PON-1 activity was increased
significantly with the intake of 3 eggs/day101.

2.4.4 Mediterranean Diet

In 1970, a researcher observed the lower incidence of CVD and certain types of cancer in
some Mediterranean countries compared to the USA or Northern Europe and hypothesized that it
was possibly due to the dietary habits of that population103. The Mediterranean diet (MedD) is a
diet consisting of fresh fish and seafood (as a source of omega-3), a moderate consumption of dairy
products, poultry and eggs and a high consumption of plant-based foods, such as fruit, vegetables,
legumes, nuts and seeds, and whole grains. Nut intake is mainly high relative to other diets. In
addition, the intake of extra virgin olive oil, as the main source of dietary lipids and as a source of
monounsaturated fatty acids (MUFA) is a unique characteristic for this diet. Another characteristic
is low frequency and amounts of red and processed meat intake104. Omega-3 and olive oil intake
have been shown to protect against factors that increase CVD risk, such as its effect on weight, in
a follow-up of a large Spanish cohort [The SUN project, Seguimiento University of Navarra], high
intakes of olive oil were not associated with increased risk of subsequent weight gain105. Also,
adherence to the MedD has been shown to reduce BP, reduce dyslipidemia, increase insulin
sensitivity, and reduce obesity (visceral obesity, which is a well-known CVD risk factor)74,75,106–
108

. In addition, in the PREDIMED study, which was a multicenter, randomized, controlled,

parallel-group clinical trial, that aims to test the efficacy of the traditional MedD as the primary
prevention of coronary heart disease, a total of 800 subjects (55-80 years) at high CVD risk who
followed the MedD with high consumption of nuts and extra virgin olive oil had reduced serum
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concentrations of inflammatory markers109. Since subjects with MetS have a low-grade
inflammation, the MedD has been shown to have health benefits and can reduce MetS metabolic
disorders, and the MedD is a lifestyle-friendly diet that could be an easy lifestyle modification for
the overweight/obese group. The 2013 report guidelines on lifestyle management from the
American Heart Association/ the American College of Cardiology71, and the European Society of
Cardiology110 all recommend the MedD as a prevention to reduce CVD risk.
These types of diets can be the primary step to prevent and reduce CVD risk factors
correlated with the presence of MetS. For that, lifestyle modification as dietary intervention and
exercise are two important factors to reduce body weight and central obesity, which can be the key
to prevent and solve this worldwide epidemic.
2.4.5 Exercise
Lifestyle modification is an important tool to reduce the future occurrence of MetS, these
changes should include both dietary intervention and increased physical activity. Diet is a crucial
key to weight loss and improve CVD risk factors as well as the activity level. According to
NHANES 2011-2014, the prevalence of low HDL-c was significantly higher among adults who
did not meet the recommended physical activity guidelines (21.0%) than adults who met the
guidelines (17.7%)111. In a meta-analysis about dietary intervention and/or physical activity on
MetS subjects the long-term, moderate to moderately vigorous intensity exercise, three to four
times per week, HDL-c concentrations were increased by 1.8 mg/dL along with decrease in TG
levels by 19 mg/dL, those results were observed on 20 randomized control studies112. Another
meta-analysis about the effects of exercise on T2D subjects has been reported. Exercise types were
either anaerobic, resistance or a combination of both, the inflammatory cytokines (CRP and IL-6)
were decreased and leptin levels were improved significantly with aerobic exercise113. Studies
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about the role of different types of exercise on subjects with MetS, such as aerobic exercise alone
versus combination of different types of exercise are insufficient, and there is a need to investigate
the role of different types of exercise on MetS parameters and whether they have different benefits
on lipid profile, which has positive effects on MetS114. Also, adequate assessment of lifestyle
modification is needed to clarify which aspects and what degree of lifestyle modification are best
to resolve MetS.
In summary, increases in MetS parameters among individuals with excess body weight can
increase risk for CVD and T2D. Both HDL-c and HDL particles can provide different benefits.
HDL particles have atheroprotective properties including antioxidant and anti-inflammatory
properties, improvements of endothelial function, and RCT process. HDL-c is a measurement that
can give some information about HDL in the circulation. Low plasma HDL-c is one of the MetS
markers and also an independent risk factor for CVD. Although pharmaceutical drugs such as
niacin and statin have an effect to increase plasma HDL-c to higher levels, the prevalence of CVD
and mortality did not change. Thus, measuring HDL functionality starts to gain attention in
research. It is known that functional HDL particles are expected to increase cholesterol efflux,
decrease inflammation, and decrease thrombosis. Some of the markers for functional HDL are apo
A-I and PON1. On the other hand, dysfunctional HDL particles are expected to decrease
cholesterol efflux, increase inflammation, and increase thrombosis. Both apo C-III and SAA1 are
two markers for dysfunctional HDL. Both diet and exercise have an effect on plasma HDL-c
concentrations and HDL particles. Therefore, controlling these two factors and measuring HDL
functionality along with measuring plasma HDL-c could be important to undrstand the effects of
lifestyle interventions.

21

References Cited
1.

WHO | Cardiovascular diseases (CVDs). WHO. 2018.
http://www.who.int/cardiovascular_diseases/en/. Accessed April 30, 2018.

2.

Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the Metabolic Syndrome in
the United States, 2003-2012. JAMA. 2015;313(19):1973.

3.

Detection EP on, Evaluation, Adults and T of HBC in. Executive summary of the third
report of the national cholesterol education program (ncep) expert panel on detection,
evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii).
JAMA. 2001;285(19):2486-2497.

4.

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause
atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and
clinical studies. A consensus statement from the European Atherosclerosis Society
Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.

5.

Fernandez ML. Metabolic Syndrome and the Components of the Mediterranean Diet.
Funct Foods Heal Dis. 2011;2(2):25-3725.
https://pdfs.semanticscholar.org/542f/149437e2d8fcea3badb0b08691436aa9858c.pdf.
Accessed February 21, 2018.

6.

Kontush A. HDL particle number and size as predictors of cardiovascular disease. Front
Pharmacol. 2015;6:218.

7.

Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and
cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15.

8.

Kosmas CE, Martinez I, Sourlas A, et al. High-density lipoprotein (HDL) functionality and
its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018;7:1-9.

9.

Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC Transporters, and
Cholesterol Efflux: Implications for the Treatment of Atherosclerosis. Cell Metab.
2008;7(5):365-375.

10.

Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their
relevance to cardiovascular disease. Trends Mol Med. 2011;17(10):594-603.

11.

Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by
raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol.
2012;167(6):1177-1194.

12.

Lund-Katz S, Phillips MC. High density lipoprotein structure-function and role in reverse
cholesterol transport. Subcell Biochem. 2010;51:183-227.

13.

Zheng C, Aikawa M. High-Density Lipoproteins. J Am Coll Cardiol. 2012;60(23):23802383.

14.

Lund-Katz S, Phillips MC. High Density Lipoprotein Structure–Function and Role in
Reverse Cholesterol Transport. In: Sub-Cellular Biochemistry. Vol 51. ; 2010:183-227.

15.

Boden WE. High-density lipoprotein cholesterol as an independent risk factor in
cardiovascular disease: assessing the data from Framingham to the Veterans Affairs
High--Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86(12A):19L-22L.
22

http://www.ncbi.nlm.nih.gov/pubmed/11374850. Accessed May 2, 2018.
16.

van der Steeg WA, Holme I, Boekholdt SM, et al. High-Density Lipoprotein Cholesterol,
High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for
Cardiovascular Risk. J Am Coll Cardiol. 2008;51(6):634-642.

17.

Nissen SE, Tardif J-C, Nicholls SJ, et al. Effect of Torcetrapib on the Progression of
Coronary Atherosclerosis. N Engl J Med. 2007;356(13):1304-1316.

18.

Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of Cholesteryl Ester Transfer
Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL.
Arterioscler Thromb Vasc Biol. 2007;27(5):1132-1138.

19.

Parish S, Offer A, Clarke R, et al. Lipids and Lipoproteins and Risk of Different Vascular
Events in the MRC/BHF Heart Protection Study. Circulation. 2012;125(20):2469-2478.

20.

Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R, Multiple Risk Factor Intervention
Trial Research Group. Lipoprotein particles, insulin, adiponectin, C-reactive protein and
risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis.
2007;195(1):122-128.

21.

Nabel EG. Cardiovascular Disease. N Engl J Med. 2003;349(1):60-72.

22.

Institutes of Health N, Heart N, Institute B. Morbidity &amp; Mortality: 2012 Chart Book on
Cardiovascular, Lung, and Blood Diseases.
https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf. Accessed
September 4, 2018.

23.

Jessup M, Brozena S. Heart Failure. N Engl J Med. 2003;348(20):2007-2018.

24.

Kwon Y-J, Lee H-S, Lee J-W. Association of carbohydrate and fat intake with metabolic
syndrome. Clin Nutr. 2018;37(2):746-751.

25.

Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men. Associations with
glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992;41(7):826-834.
http://www.ncbi.nlm.nih.gov/pubmed/1612197. Accessed September 5, 2018.

26.

Carey DG, Jenkins AB, Campbell L V, Freund J, Chisholm DJ. Abdominal fat and insulin
resistance in normal and overweight women: Direct measurements reveal a strong
relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45(5):633638. http://www.ncbi.nlm.nih.gov/pubmed/8621015. Accessed August 30, 2018.

27.

de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip
ratio as predictors of cardiovascular events: meta-regression analysis of prospective
studies. Eur Heart J. 2007;28(7):850-856.

28.

Kenchaiah S, Evans JC, Levy D, et al. Obesity and the Risk of Heart Failure. N Engl J
Med. 2002;347(5):305-313.

29.

Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality.
The Framingham Heart Study. Arteriosclerosis. 8(6):737-741.
http://www.ncbi.nlm.nih.gov/pubmed/3196218. Accessed September 6, 2018.

30.

Rosales C, Gillard BK, Gotto AM, Pownall HJ. High-Density Lipoprotein Processing and
Premature Cardiovascular Disease. Methodist Debakey Cardiovasc J. 2015;11(3):181185.
23

31.

Holvoet P, De Keyzer D, Jacobs Jr DR. Oxidized LDL and the metabolic syndrome.
Future Lipidol. 2008;3(6):637-649.

32.

Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of
Metabolic Syndrome on Biomarkers of Oxidative Stress and Inflammation in Obese
Adults*. Obesity. 2006;14(12):2127-2131.

33.

O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its
associated pathologies. Obes Rev. 2015;16(1):1-12.

34.

Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. Obes
Res. 1996;4(2):201-203. http://www.ncbi.nlm.nih.gov/pubmed/8681056. Accessed August
30, 2018.

35.

Haller H, Hanefeld M. Synoptische Betrachtung metabolischer Risikofaktoren. Haller H
Hanefeld M Jaross W eds Lipidstoffwechselstörungen. 1975:254-264.

36.

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes.
1988;37(12):1595-1607. http://www.ncbi.nlm.nih.gov/pubmed/3056758. Accessed August
9, 2018.

37.

Juonala M, Magnussen CG, Berenson GS, et al. Childhood Adiposity, Adult Adiposity,
and Cardiovascular Risk Factors. N Engl J Med. 2011;365(20):1876-1885.

38.

Melin EO, Thulesius HO, Hillman M, Landin-Olsson M, Thunander M. Abdominal obesity
in type 1 diabetes associated with gender, cardiovascular risk factors and complications,
and difficulties achieving treatment targets: a cross sectional study at a secondary care
diabetes clinic. BMC Obes. 2018;5:15.

39.

Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic
syndrome---An American Heart Association/National Heart, Lung, and Blood Institute
Scientific Statement. Circulation. 2005;112.

40.

Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by
Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination
Survey, 1988–2012. Prev Chronic Dis. 2017;14:160287.

41.

Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by
Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination
Survey, 1988–2012. Prev Chronic Dis. 2017;14:160287.

42.

Rolfes SR, Pinna K, Whitney EN. Understanding Normal and Clinical Nutrition. Belmont,
CA: Wadsworth/Cengage Learning; 2009.

43.

Gropper SAS. Advanced Nutrition and Human Metabolism. 6th ed.. (Smith JL, Groff JL,
eds.). Australia: Australia; 2009.

44.

Hirowatari Y, Tsunoda Y, Ogura Y, Homma Y. Analyzing of high-density lipoprotein
subfractions and low-density lipoprotein subfractions in human serum with anionexchange chromatography. Atherosclerosis. 2009;204(2):e52-e57.

45.

Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc
Pharmacol. 2012;10(4):410-421. http://www.ncbi.nlm.nih.gov/pubmed/22339300.
Accessed September 15, 2018.

46.

Miller NE. HDL metabolism and its role in lipid transport. Eur Heart J. 1990;11 Suppl H:124

3. http://www.ncbi.nlm.nih.gov/pubmed/2073908. Accessed September 13, 2018.
47.

Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014.

48.

Zannis VI, Fotakis P, Koukos G, et al. HDL Biogenesis, Remodeling, and Catabolism. In:
Springer, Cham; 2015:53-111.

49.

Hafiane A, Genest J. High density lipoproteins: Measurement techniques and potential
biomarkers of cardiovascular risk. BBA Clin. 2015;3:175-188.

50.

Speer T, Rohrer L, Blyszczuk P, et al. Abnormal High-Density Lipoprotein Induces
Endothelial Dysfunction via Activation of Toll-like Receptor-2. Immunity. 2013;38(4):754768.

51.

Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity.
Circulation. 1966;34(4):679-697. http://www.ncbi.nlm.nih.gov/pubmed/5921763.
Accessed September 14, 2018.

52.

Francis GA. The complexity of HDL. Biochim Biophys Acta - Mol Cell Biol Lipids.
2010;1801(12):1286-1293.

53.

Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: An Oxidative Pathway for
Generating Dysfunctional High-Density Lipoprotein. Chem Res Toxicol. 2010;23(3):447454.

54.

Rashid S, Genest J. Effect of Obesity on High-density Lipoprotein Metabolism**. Obesity.
2007;15(12):2875-2888.

55.

Karadag MK, Akbulut M. Low HDL levels as the most common metabolic syndrome risk
factor in heart failure. Int Heart J. 2009;50(5):571-580.
http://www.ncbi.nlm.nih.gov/pubmed/19809206. Accessed September 15, 2018.

56.

Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus
on antioxidative activities. Curr Opin Lipidol. 2010;21(4):312-318.

57.

Haynes R, Jiang L, Hopewell JC, et al. HPS2-THRIVE randomized placebo-controlled
trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle
and liver outcomes, and reasons for stopping study treatment. Eur Heart J.
2013;34(17):1279-1291.

58.

von Eckardstein A. Implications of torcetrapib failure for the future of HDL therapy: is
HDL-cholesterol the right target? Expert Rev Cardiovasc Ther. 2010;8(3):345-358.

59.

Kontush A. HDL particle number and size as predictors of cardiovascular disease. Front
Pharmacol. 2015;6:218.

60.

Böttcher A, Schlosser J, Kronenberg F, et al. Preparative free-solution isotachophoresis
for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL
subfractions. J Lipid Res. 2000;41(6):905-915.
http://www.ncbi.nlm.nih.gov/pubmed/10828082. Accessed September 17, 2018.

61.

Freeman LA. Native–Native 2D Gel Electrophoresis for HDL Subpopulation Analysis. In:
Methods in Molecular Biology (Clifton, N.J.). Vol 1027. ; 2013:353-367.

62.

Ito K, Yoshida H, Yanai H, et al. Relevance of intermediate-density lipoprotein cholesterol
to Framingham risk score of coronary heart disease in middle-aged men with increased
non-HDL cholesterol. Int J Cardiol. 2013;168(4):3853-3858.
25

63.

Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein Particle
Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and
Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. Circulation.
2009;119(7):931-939.

64.

Blesso CN, Andersen CJ, Barona J, Volek JS, Fernandez ML. Whole egg consumption
improves lipoprotein profiles and insulin sensitivity to a greater extent than yolk-free egg
substitute in individuals with metabolic syndrome. 2013.

65.

Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant.
Eur J Biochem. 1999;265(2):501-523. http://www.ncbi.nlm.nih.gov/pubmed/10504381.
Accessed September 18, 2018.

66.

Hua S, Song C, Geczy CL, Freedman S Ben, Witting PK. A role for acute-phase serum
amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and
atherosclerosis. Redox Rep. 2009;14(5):187-196.

67.

Xiong X, Liu H, Hua L, Zhao H, Wang D, Li Y. The association of HDL-apoCIII with
coronary heart disease and the effect of statin treatment on it. Lipids Health Dis.
2015;14(1):127.

68.

Rochu D, Chabrière E, Masson P. Paraoxonase-1 and its Interactions with HDL:
Molecular Structures of PON1 and HDL. HDL Handb. January 2010:99-131.

69.

Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and
expression, promiscuous activities and multiple physiological roles. Gene.
2015;567(1):12-21.

70.

Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on
eNOS-activating pathways in patients with coronary artery disease. J Clin Invest.
2011;121(7):2693-2708.

71.

Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on Lifestyle Management
to Reduce Cardiovascular Risk. Circulation. 2014;129(25 suppl 2):S76-S99.

72.

Buckland G, Bach A, Serra-Majem L. Obesity and the Mediterranean diet: a systematic
review of observational and intervention studies. Obes Rev. 2008;9(6):582-593.

73.

Al-Sarraj T, Saadi H, Volek JS, Fernandez ML. Carbohydrate restriction favorably alters
lipoprotein metabolism in Emirati subjects classified with the metabolic syndrome. Nutr
Metab Cardiovasc Dis. 2010;20(10):720-726.

74.

Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB.
The Effect of Mediterranean Diet on Metabolic Syndrome and its Components. J Am Coll
Cardiol. 2011;57(11):1299-1313.

75.

Grosso G, Mistretta A, Frigiola A, et al. Mediterranean Diet and Cardiovascular Risk
Factors: A Systematic Review. Crit Rev Food Sci Nutr. 2014;54(5):593-610.

76.

Grosvenor MB. Nutrition: From Science to Life. John Wiley & Sons, Incorporated; 2001.
https://books.google.com/books?id=NLQKGQAACAAJ.

77.

Wing RR, Lang W, Wadden TA, et al. Benefits of Modest Weight Loss in Improving
Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes.
Diabetes Care. 2011;34(7):1481-1486.

26

78.

Rossmeislová L, Mališová L, Kračmerová J, Štich V. Adaptation of human adipose tissue
to hypocaloric diet. Int J Obes. 2013;37(5):640-650.

79.

Look AHEAD Research Group, Wing RR. Long-term Effects of a Lifestyle Intervention on
Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus.
Arch Intern Med. 2010;170(17):1566-1575.

80.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and
Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6
Suppl 2:51S-209S. http://www.ncbi.nlm.nih.gov/pubmed/9813653. Accessed August 22,
2018.

81.

Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving
cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.
Diabetes Care. 2011;34(7):1481-1486.

82.

Accurso A, Bernstein RK, Dahlqvist A, et al. Dietary carbohydrate restriction in type 2
diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab
(Lond). 2008;5:9.

83.

Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in
patients with non-insulin-dependent diabetes mellitus. JAMA. 1994;271(18):1421-1428.
http://www.ncbi.nlm.nih.gov/pubmed/7848401. Accessed September 1, 2018.

84.

Wood RJ, Volek JS, Liu Y, Shachter NS, Contois JH, Fernandez ML. Carbohydrate
Restriction Alters Lipoprotein Metabolism by Modifying VLDL, LDL, and HDL Subfraction
Distribution and Size in Overweight Men. J Nutr. 2006;136(2):384-389.

85.

Sun F-H, Li C, Zhang Y-J, Wong S, Wang L. Effect of Glycemic Index of Breakfast on
Energy Intake at Subsequent Meal among Healthy People: A Meta-Analysis. Nutrients.
2016;8(1):37.

86.

Brand-Miller J, McMillan-Price J, Steinbeck K, Caterson I. Dietary glycemic index: health
implications. J Am Coll Nutr. 2009;28 Suppl:446S-449S.
http://www.ncbi.nlm.nih.gov/pubmed/20234031. Accessed September 1, 2018.

87.

Reaven GM. Effect of dietary carbohydrate on the metabolism of patients with non-insulin
dependent diabetes mellitus. Nutr Rev. 1986;44(2):65-73.
http://www.ncbi.nlm.nih.gov/pubmed/3703391. Accessed August 30, 2018.

88.

Volek JS, Feinman RD. Carbohydrate restriction improves the features of Metabolic
Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate
restriction. Nutr Metab (Lond). 2005;2(1):31.

89.

Mozaffarian D, Ludwig DS. The 2015 US Dietary Guidelines. JAMA. 2015;313(24):2421.

90.

Westman EC, Yancy WS, Olsen MK, Dudley T, Guyton JR. Effect of a low-carbohydrate,
ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int J
Cardiol. 2006;110(2):212-216.

91.

Ruaño G, Windemuth A, Kocherla M, et al. Physiogenomic analysis of weight loss
induced by dietary carbohydrate restriction. Nutr Metab (Lond). 2006;3:20.

92.

Pan W-H, Yeh W-T, Weng L-C. Epidemiology of metabolic syndrome in Asia. Asia Pac J
Clin Nutr. 2008;17 Suppl 1:37-42. http://www.ncbi.nlm.nih.gov/pubmed/18296297.
Accessed August 31, 2018.
27

93.

Wood RJ, Volek JS, Davis SR, Dell’Ova C, Fernandez ML. Effects of a carbohydraterestricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab
(Lond). 2006;3:19.

94.

Foster GD, Wyatt HR, Hill JO, et al. A Randomized Trial of a Low-Carbohydrate Diet for
Obesity. N Engl J Med. 2003;348(21):2082-2090.

95.

Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of Low-Fat vs LowCarbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association
With Genotype Pattern or Insulin Secretion. JAMA. 2018;319(7):667.

96.

Wood RJ, Volek JS, Davis SR, Dell’Ova C, Fernandez ML. Effects of a carbohydraterestricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab
(Lond). 2006;3:19.

97.

DiMarco DM, Missimer A, Murillo AG, et al. Intake of up to 3 Eggs/Day Increases HDL
Cholesterol and Plasma Choline While Plasma Trimethylamine-N-oxide is Unchanged in
a Healthy Population. Lipids. 2017.

98.

Andersen CJ, Blesso CN, Lee J, et al. Egg Consumption Modulates HDL Lipid
Composition and Increases the Cholesterol-Accepting Capacity of Serum in Metabolic
Syndrome. Lipids. 2013;48(6):557-567.

99.

Burgess JW, Neville TA-M, Rouillard P, Harder Z, Beanlands DS, Sparks DL.
Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res. 2005;46(2):350-355.

100. Missimer A, Fernandez ML, DiMarco DM, et al. Compared to an Oatmeal Breakfast, Two
Eggs/Day Increased Plasma Carotenoids and Choline without Increasing Trimethyl
Amine N -Oxide Concentrations. J Am Coll Nutr. 2018.
101. DiMarco DM, Norris GH, Millar CL, Blesso CN, Fernandez ML. Intake of up to 3 Eggs per
Day Is Associated with Changes in HDL Function and Increased Plasma Antioxidants in
Healthy, Young Adults. J Nutr. 2017;147(3):323-329.
102. Clayton ZS, Fusco E, Kern M. Egg consumption and heart health: A review. Nutrition.
2017;37:79-85.
103. Keys A, Menotti A, Karvonen MJ, et al. The diet and 15-year death rate in the seven
countries study. Am J Epidemiol. 1986;124(6):903-915.
http://www.ncbi.nlm.nih.gov/pubmed/3776973. Accessed August 27, 2018.
104. Babio N, Bulló M, Salas-Salvadó J. Mediterranean diet and metabolic syndrome: the
evidence. Public Health Nutr. 2009;12(9A):1607.
105. Martínez-González MA. The SUN cohort study (Seguimiento University of Navarra).
Public Health Nutr. 2006;9(1A):127-131. http://www.ncbi.nlm.nih.gov/pubmed/16512960.
Accessed August 28, 2018.
106. Carlos S, De La Fuente-Arrillaga C, Bes-Rastrollo M, et al. Mediterranean Diet and
Health Outcomes in the SUN Cohort. Nutrients. 2018;10(4):439.
107. Saibandith B, Spencer JPE, Rowland IR, Commane DM. Olive Polyphenols and the
Metabolic Syndrome. Molecules. 2017;22(7):1082.
108. Park Y-M, Zhang J, Steck SE, et al. Obesity Mediates the Association between
Mediterranean Diet Consumption and Insulin Resistance and Inflammation in US Adults.
28

J Nutr. 2017;147(4):563-571.
109. Martínez-González MA, Salas-Salvadó J, Estruch R, et al. Benefits of the Mediterranean
Diet: Insights From the PREDIMED Study. Prog Cardiovasc Dis. 2015;58(1):50-60.
110. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease
prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in
Clinical Practice (constituted by representatives of nine societies and by invited experts) *
Developed with the special contribution of the European Association for Cardiovascular
Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2012;33(13):1635-1701.
111. Zwald ML, Akinbami LJ, Fakhouri THI, Fryar CD. Prevalence of Low High-density
Lipoprotein Cholesterol Among Adults, by Physical Activity: United States, 2011-2014.
NCHS Data Brief. 2017;(276):1-8. http://www.ncbi.nlm.nih.gov/pubmed/28282020.
Accessed September 20, 2018.
112. Carroll S, Dudfield M. What is the relationship between exercise and metabolic
abnormalities? A review of the metabolic syndrome. Sports Med. 2004;34(6):371-418.
http://www.ncbi.nlm.nih.gov/pubmed/15157122. Accessed August 28, 2018.
113. Hayashino Y, Jackson JL, Hirata T, et al. Effects of exercise on C-reactive protein,
inflammatory cytokine and adipokine in patients with type 2 diabetes: A meta-analysis of
randomized controlled trials. Metabolism. 2014;63(3):431-440.
114. Yamaoka K, Tango T. Effects of lifestyle modification on metabolic syndrome: a
systematic review and meta-analysis. BMC Med. 2012;10(1):138.

29

Chapter 3
Materials and Methods

3.1 Study Design
Data for this project was obtained from recruited subjects of a study conducted at the
University of Connecticut1. This observational study included men and women, aged 32-70 years
old, and classified with MetS. The study was approved by the University of Connecticut
Institutional Review Board (IRB H14-278). All subjects signed a written consent form prior to
joining the study. The study was registered at Clinicaltrials.gov, protocol # NCT02531334.
Every subject that was accepted in the study underwent a screening evaluation to determine
whether they classified for MetS. The screening involved anthropometric measurements including
weight, height, waist circumference and BMI as well as plasma values for triglycerides (TG),
HDL-c and glucose, and blood pressure (BP).
3.2 Subjects
Data were collected from 40 overweight and obese men (n=11) and women (n=29), 32-70
years old who met the proper criteria. The MetS criteria were in accordance with the NCEP:ATP
III definition2, which is having any 3 or more of the following 5 characteristics: BP ≥ 130/85 mm
Hg (either number, or use of antihypertensive medications); plasma glucose ≥ 100 mg/dL; TG ≥
150 mg/dL, waist circumference (WC) ≥ 102 cm for men or ≥ 88 cm for women, and HDL-c <
40 mg/dL for men or < 50 mg/dL for women2. Subjects had no current or history of heart disease,
stroke, diabetes, liver disease, cancer, severe infections or autoimmune diseases. Subjects with
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MetS were classified into two groups according to their HDL-c concentrations; Normal HDL-c
group (n=23), (men=6; women=17), and Low HDL-c group (n=17), (men=5; women= 12).
*Normal HDL-c → men ≥ 40 mg/dL and women ≥ 50 mg/dL.
*Low HDL-c → men < 40 mg/dL and women < 50 mg/dL.
3.3 Anthropometrics
Weight in kilograms (kg) was measured to the closest 0.1kg on a portable scale and height
in centimeters (cm) was measured to the closest 0.5 cm on a stadiometer. Both weight and height
were used to calculate body mass index (BMI) in kg/m2 as the following equation: BMI= weight
(kg)/ height (m2). WC was assessed with a flexible measuring tape that was placed at the top of
the iliac crest directly on the skin, and subjects were standing forward, feet together, with both
arms hanging freely. WC were averaged from 3 readings to the nearest 0.5 cm3. BP was measured
on the right arm using an Omron automated BP cuff (Omron HEM 7320-Z/ HEM 7131-Z, Lake
Forest, IL, USA), with subjects sitting quietly for 1-3 minutes rest. BP was measured from an
average of 3 readings taken by the same individual to account for variability4.
3.4 Diet and Exercise Analysis
Diet Records Assessment was conducted through the analysis of 3-day diet records
completed by participants at baseline. Participants were given instructions on how to fill out the
diet records. Nutrition Data Systems for Research software (NDSR; 2013), developed by the
Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN, USA, was used to
analyze the diet records8. Subjects completed a 3-day exercise records, and an average was
calculated to use for analysis.
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3.5 Blood Analysis
After a 12 hour overnight fast, blood samples were drawn from each subject. A total of 40
ml blood was collected from the antecubital vein into Ethylenediaminetetraacetic acid (EDTA)containing tubes to prevent coagulation. A sample of whole blood (1ml) was collected and frozen
at -80 degrees Celsius for further analysis. Plasma was isolated by centrifugation at 2000 x g for
20 minutes, and then 500 µl of plasma were used in Cobas c-111analyzer (Roche Diagnostics,
Indianapolis, IN)5 to determine plasma lipids, glucose, liver enzymes and C-reactive protein
(CRP). The remaining plasma was aliquoted and frozen at -80 degrees C° for further analysis.
3.5.1 Lipid Analysis, Glucose, Glycosylated Hemoglobin (HbA1c), Liver Enzymes, C-Reactive
Protein and Insulin
Plasma total cholesterol (TC), TG, glucose, HDL-c, CRP, liver enzymes alanine
aminotransferase (ALT) and aspartate aminotransferase (AST), and HbA1c were all determined
using an automated clinical chemistry analyzer (Cobas c-111, Roche Diagnostics, Indianapolis,
IN) via enzymatic reactions and photometric detection method5. Plasma LDL-c was calculated by
the Friedewald equation: LDL-c= TC - HDL-c - (TG/5). This equation was based on measurements
of plasma TC, HDL-c and TG in mg/dL, and become the standard method for LDL-c assessment
because it is simpler than direct assays6. Plasma insulin was measured by an ELISA kit (Crystal
Chem, Elk Grove Village, IL), which utilizes a specific antibody immobilized onto the 96microplate wells and an antibody labeled with HRP enzyme. After incubation and washout steps
the substrate solution was added followed by incubation in the dark for 15 minutes. Then the stop
solution was added and the insulin levels of samples were measured according color intensity by
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using a BioTek Synergy 2 Multi-Mode Microplate Reader with Gen5 Software (BioTek
Instruments, Inc.) at wavelength 450nm7.
3.5.2 Lipoproteins Size and Subfractions
Fasting plasma was used to determine total lipoprotein particle number, size, and
concentration using proton nuclear magnetic resonance (NMR) spectroscopy. NMR analysis was
performed on 400 MHz NMR analyzer (LipoScience, Inc., Raleigh, NC) 8. This technique can
quantify the size, number, and concentration of lipoprotein particles expressed each as an average
particle size or as lipoprotein particle concentration by a specific methyl signal9. The NMR
simultaneously quantifies >30 lipoprotein fractions that are grouped into subclasses based on size.
The lipoprotein subtractions were: small VLDL (27–35 nm), medium VLDL (35–60 nm), large
VLDL (>60 nm), IDL (23–27 nm), small LDL (18–19.8 nm), medium LDL (19.8–21.2 nm), large
LDL (21.2–23 nm), small HDL (7.3–8.2 nm). medium HDL (8.2–8.8 nm), and large HDL (8.8–
13 nm).
3.5.3 Apolipoprotein Analysis
Plasma apolipoproteins (apo A-I, apo A-II, apo B, apo C-II, apo C-III, and apo E) were
quantified simultaneously by using a commercially human apolipoprotein multiplex assay kit
(EMD Millipore, Billerica, MA) and analyzed by a Luminex MAGPIX analyzer (Luminex
Corporation, Austin, Texas, United States)8. This procedure quantifies apolipoproteins in plasma
using antibody-immobilized fluorescent dye labeled microspheres.
3.5.4 HDL Functionality: PON1 and SAA1
Plasma PON1 activity was measured by a commercial fluorometric assay kit (BioVision,
Inc, Milpitas, CA)10. This assay kit enables rapid measurement of PON1 activity through utilizing
33

a fluorogenic substrate that is converted into a highly fluorescent product (Ex/Em = 368/460 nm).
Plasma samples, standards, positive and negative controls were added to black 96- fluorescence
microplate wells. The reactions were carried out according to the manufacturer’s instructions and
the fluorescence levels were measured in kinetic mode for 60 minutes at 37 degrees Celsius by
BioTek Synergy H1 Microplate Fluorescence Reader with Gen5 Software (BioTek Instruments,
Inc.; Winooski, VT, USA). Calculations were made by using the following formula:
Sample PON1 Activity = 𝑩/ Δ𝑻×𝑽 = pmol/min/ml = U/ml
Where: B = the amount of metabolite produced, calculated from the standard curve (in pmol)
ΔT = the linear phase reaction time t2 – t1 (in minutes)
V = the volume of sample added to the well (in ml)
Plasma SAA1 was measured by a ProcartaPlex Multiplex Immunoassay Human assay kit
(Invitrogen, Vienna, Austria). This kit is used to perform quantitative multiplexed protein
measurements in plasma samples using magnetic beads technology from Luminex to enable the
simultaneous detection of SAA111. Samples and standards were added to the black 96- microplate.
The protocol was followed according to the manufacturer’s instructions and the samples were
diluted 1:200. After the last incubation at room temperature on a plate shaker and the addition of
reading buffer to all wells, the analysis was done by using a Luminex MAGPIX analyzer (Luminex
Corporation, Austin, Texas, United States).
3.5.5 Plasma Inflammatory Biomarkers
Plasma tumor necrosis factor- (TNF-), monocyte chemoattractant protein-1 (MCP-1),
Interleukin (IL)-6 and IL-8, were measured by use of the LINCOplex: Multiplex Biomarker
Immunoassay for Luminex MAGPIX Technology (Luminex Corporation, Austin, Texas, United
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States). This technique uses the fluorescently labeled microsphere beads with antibodies to each
individual cytokine12.
3.5.6 Plasma Antioxidant and Oxidative Stress Biomarkers and Oxidized LDL
Plasma glutathione peroxidase (GPx), superoxide dismutase (SOD), total antioxidant
capacity (TAC), and catalase were measured using commercially available kits (Cayman Chemical
Company, Ann Arbor, MI). The activity of GPx was measured indirectly by a coupled reaction
with glutathione reductase 13. SOD activity was determined by measuring the extent of superoxide
radical generation by xanthine oxidase and hypoxanthine 14. TAC was measured by assessing the
oxidation extent of 2,2’-Azino-di-3-ethylbenzthiazoline sulfonate14. Catalase activity was assessed
by measuring formaldehyde production in the presence of hydrogen peroxide. Thiobarbituric acid
reactive substances (TBARS) were assessed as a marker of lipid peroxidation by using a
commercially available kit (R&D Systems, Minneapolis, MN)15 and a BioTek Synergy 2 MultiMode Microplate Reader with Gen5 Software (BioTek Instruments, Inc.) for measuring the
absorbance.
Ox-LDL was measured using a solid phase capture sandwich enzyme linked
immunosorbent assay (ELISA) technology5. The 96-microwell plate to which the samples and
standards were added was coated with antioxidized LDL antibodies. After the washout step, HRP
enzyme was added and then TMB substrates. TMB was catalyzed by HRP to produce a blue color
that changed into yellow after adding the stop solution. The intensity of the yellow color is directly
proportional to the concentration of Ox-LDL on the plate. The Ox-LDL concentrations were
measured by using a BioTek Synergy 2 Multi-Mode Microplate Reader with Gen5 Software
(BioTek Instruments, Inc.) at wavelength: 450nm.
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3.6 Statistical Analysis
Statistical analysis was performed using SPSS version 25 statistical software for Windows
(SPSS, Inc., Chicago, IL). Significance was defined as p < 0.05. Data values were represented as
mean ± standard deviation (SD). Un-paired t tests were used to determine significant differences
between the groups in plasma lipids, apoproteins, lipoprotein subfractions, plasma inflammatory
biomarkers, plasma antioxidant biomarkers and anthropometric measurements. Pearson
correlations were used to evaluate positive and/or negative relationships between HDL level and
lipoprotein size and number.
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Chapter 4
Results

4.1 Baseline Characteristics
To assess whether low HDL-c concentrations are associated with the biomarkers of
cardiovascular disease, 40 subjects who classified with MetS according to the NCEP:ATP III
criterion were divided into two groups based on plasma HDL-c concentrations into Normal HDLc [men ≥ 40 mg/dL and women ≥ 50 mg/dL] and Low HDL-c [men < 40 mg/dL and women < 50
mg/dL]. Subject’s diet intake and exercise records are shown in Table 1. There were no significant
differences between the two groups in any of the analyzed nutrients including macronutrients,
types of fat, glycemic index, fiber or carotenoids. Similarly, there were not significant differences
in terms of minutes exercise per day in both groups. Subject’s age ranged from 32 -70 years old
and their anthropometric measurements are displayed in Table 2. Based on BMI values, the
majority of subjects were in the obese category (n=27). WC on average was 106.9 cm for the
Normal HDL-c group and 110 cm for the Low HDL-c group. Plasma HDL-c on average was 61.4
mg/dL in subjects with Normal HDL-c and 38.5 mg/dL in subjects with Low HDL-c. Systolic
blood pressure (BP) as well as TG were different between groups. The Low HDL-c group had
significantly higher systolic BP and TG than Normal HDL-c group (p < 0.01). Other MetS
parameters (WC, fasting glucose and diastolic BP) were not different between groups. A negative
correlation was found between HDL-c and waist circumference (WC) (r= -.0418, p < 0.01) and
between HDL-c and insulin (r= - 0.413, p < 0.025) as presented in Figure 1 and Figure 2,
respectively. In addition, a positive correlation was found between TG and insulin values as
presented in Figure 3.
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Table 1. Diet and exercise records in Normal HDL-c and Low HDL-c groups

Parameter

Normal HDL-c

Low HDL-c

P value

Total Energy (kcal)

2051.4 ± 891.6

2025.1 ± 472.3

0.913

Carbohydrate (%)

38.3 ± 9.0

40.4 ± 6.7

0.408

Protein (%)

17.2 ± 2.9

18.3 ± 3.8

0.315

Fat (%)

41.2 ± 8.6

39.1 ± 7.4

0.428

SFA (g/day)

30.3 ± 12.2

31.4 ± 15.1

0.797

MUFA (g/day)

39.7 ± 41.8

32.9 ± 11.9

0.523

PUFA (g/day)
Trans Fatty Acids
(g/day)
Cholesterol (mg/day)

21.3 ± 17.5

19.5 ± 6.4

0.676

2.5 ± 2.3

2.1 ± 0.94

311.0 ± 139.7

311.7 ± 193.2

0.990

Total Fiber (g/day)

21.8 ± 14.8

24.1 ± 10.3

0.590

Soluble Fiber (g/day)

6.7 ± 2.2

7.7 ± 2.4

0.224

Insoluble Fiber (g/day)

14.9 ± 13.5

16.4 ± 8.5

0.700

Glycemic Index

57.7 ± 6.1

56.6 ± 5.6

0.577

Glycemic Load

101.7 ± 44.2

106.4 ± 34.5

0.720

β-Carotene (μg)

3423.4 ± 3255.9

3886.2 ± 3430.1

0.666

α-Carotene (μg)
Lycopene (μg)

577.7 ± 1045.2

645.8 ± 924.4

0.832

6522.7 ± 7733.0

3959.8 ± 4016.2

0.221

Lutein + Zeaxanthin
2390.8 ± 2108.9
(µg/day)
Exercise
36.7 ± 29.8
(minutes/week)
- Data presented as Mean ± SD

3830.7 ± 4787.4
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53.8 ± 50

0.250

0.206
0.185

Table 2. Anthropometrics, blood pressure (BP), plasma total cholesterol (TC), triglycerides
(TG), HDL-c, LDL-c, plasma glucose, plasma insulin and glycosylated hemoglobin (HbA1c) in
Normal HDL-c and Low HDL-c groups
Parameter

Normal HDL-c

Low HDL-c

P value

Age (years)

53.3 ± 9.4

51.2 ± 9.8

0.492

Weight (kg)

88.6 ± 17.3

93.6 ± 14.6

0.341

BMI (kg/m2)

32 ± 4.1

32.7 ± 3.3

0.563

114.2 ± 15.5 (men)

113.6 ± 11.5 (men)

0.948

104.4 ± 8.3 (women)

108.5 ± 9.5 (women)

0.231

WC (cm)
Both genders
Systolic BP (mm Hg)

106.9 ± 11.2

109 ± 10.1

0.381

121.3 ± 14.2

129.9 ± 9.8

Diastolic BP (mm Hg)

84.8 ± 7.1

83.1 ± 9.1

0.507

TC (mg/dL)

187.4 ± 36.3

178.6 ± 30.8

0.426

TG (mg/dL)

115.5 ± 56.8

165.7 ± 80.7

0.026

47.2 ± 5.1 (men)

31.6 ± 3.8 (men)

0.000

66.5 ± 18.6 (women)

41.4 ± 3.8 (women)

0.000

61.4 ± 18.2

38.5 ± 5.9

0.000

LDL-c (mg/dL)

102.7 ± 31.7

107 ± 29.6

0.662

Glucose (mg/dL)

106.2 ± 10.1

105.1 ± 9.9

0.733

Insulin (pmol/L)

45.6 ± 29.9

60.3 ± 29.1

0.141

HbA1c (%)

5.6 ± 0.45

5.6 ± 0.58

0.815

WC (cm)

0.028

HDL-c (mg/dL)

HDL-c (mg/dL)
Both genders

- Data presented as Mean ± SD
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Figure 1. Negative correlation between HDL-c concentrations and waist circumference (WC)

Figure 2. Negative correlation between HDL-c concentrations and insulin
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Figure 3. Positive correlation between TG levels and insulin
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4.2 Lipoprotein Size and Subfractions
VLDL, LDL and HDL size as well as VLDL, LDL and HDL subfractions were assessed
using NMR spectroscopy. Numbers, size, and total of each lipoprotein. Total VLDL particles in
Normal HDL-c group and Low HDL-c group are presented in Figure 4. Large and medium sizes
of VLDL particles were significantly higher in the Low HDL-c group [large: p= 0.028; medium:
p= 0.005] as presented in Figure 5. In addition, total LDL particles in Normal HDL-c group and
Low HDL-c group are presented in Figure 6. As shown in Figure 7, large LDL particles, which
are the less atherogenic lipoprotein were lower in the Low HDL-c group while small LDL particles,
which are known to be the most atherogenic lipoprotein were higher when compared with Normal
HDL-c [ large LDL: p= 0.012, and small LDL: p= 0.002]. Total HDL particles were lower
significantly in the Low HDL-c group compared to the Normal HDL-c group (p =0.000), as shown
in Figure 8. In addition, HDL particles distributions are presented in Figure 9. Large HDL
particles were lower significantly in the Low HDL-c group compared to the Normal HDL-c group
(p <0.05). LDL and HDL particles as measured in nanometers were lower in the Normal HDL-c
group compared to the Low HDL-c group as presented in Figure 10.
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Figure 4. Total VLDL particles (nmol/L) in Normal HDL-c and Low HDL-c groups

Figure 5. Concentrations of large, medium and small VLDL (nmol/L) in Normal HDL-c and
Low HDL-c groups

p < 0.05
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Small VLDL

Figure 6. Total LDL particles (nmol/L) in Normal HDL-c and Low HDL-c groups

Figure 7. Concentrations of large and small LDL (nmol/L) in Normal HDL-c and Low HDL-c
groups

p < 0.05
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Figure 8. Total HDL particles (µmol/L) in Normal HDL-c and Low HDL-c groups

Figure 9. Concentrations of large, medium and small HDL (µmol/L) in Normal HDL-c and Low
HDL-c groups

p < 0.05
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Figure 10. Lipoprotein size (nm) in Normal HDL-c and Low HDL-c groups
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4.3 Apolipoproteins (apo) Distribution based on Plasma HDL-c
The distribution of apo A-I, apo A-II, apo C-II, apo C-III, apo E, and apo B in the plasma
was assessed using a human apolipoprotein multiplex assay kit to compare apolipoproteins
distribution between the two groups as presented in Table 3. Apo A-I was significantly lower in
Low HDL-c group compared to the Normal HDL-c group. None of the other apolipoproteins were
statistically significant between groups. There was positively correlation between Apo A-I and
large HDL particles that presented in Figure 11. Also, there was a positive correlation between
Apo A-I and total HDL in Figure 12. When waist measurement increased, apo A-I is that mainly
present in HDL particles was decreased that was presented as a negative correlation between WC
and apo A-I in Figure 13. There was a positive correlation between TG and apo C-III that
presented in Figure 14.
Table 3: Apolipoproteins distribution based on plasma HDL-c
Parameter

Normal HDL-c

Low HDL-c

P value

Apo A-I (mg/L)

985.4 ± 274.2

790.7 ± 188.1

0.019

Apo A-II (mg/L)

599.0 ± 159.4

586.4 ± 173.9

0.813

Apo C-II (mg/L)

243.4 ± 161.1

283.8 ± 212.5

0.497

Apo C-III (mg/L)

474.7 ± 274.1

520.1 ± 330.8

0.639

Apo E (mg/L)

106.2 ± 60.4

125.3 ± 62.9

0.339

Apo B (mg/L)

1707.1 ± 704.4

1908.8 ± 598.0

0.346

- Data presented as Mean ± SD
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Figure 11. Positive correlation between large HDL and Apo A-I

r = 0.530, p < 0.01
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Figure 12. Positive correlation between total HDL and Apo A-I
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Figure 13. Negative correlation between WC and Apo A-I

Figure 14. Positive correlation between TG and Apo C-III
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4.4 HDL Functionality [PON-1 and SAA1]

PON-1 was assessed as a functional marker for HDL particles, its activity was measured
by using a fluorometric assay kit. PON-1 activity values for both groups are presented in Figure
15. PON-1 values were significantly higher in the Normal HDL-c compared to the Low HDL-c
group (p= 0.022). In Figure 16, a positive correlation was found between PON-1 and total HDL.
SAA1 was measured as a functional marker for HDL. In Figure 17, SAA1 values are presented
for both Normal HDL-c group and Low HDL-c group. There were no significant differences
between groups. In addition, there was a positive correlation between SAA1 and the inflammatory
marker CRP that is presented in Figure 18.

Figure 15. Paraoxonase-1 (PON-1) activity in Normal HDL-c and Low HDL-c groups
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Figure 16. Positive correlation between PON-1 and total HDL

Figure 17. Serum Amyloid A1 (SAA1) in Normal HDL-c and Low HDL-c groups
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Figure 18. Positive correlation between CRP and SAA1
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4.5 Inflammatory Markers
Mean values for inflammatory markers [liver enzymes [alanine aminotransferase (ALT)
and aspartate aminotransferase (AST)], C-reactive protein (CRP), tumor necrosis factor- (TNF), monocyte chemoattractant protein-1 (MCP-1), and Interleukin (IL)-6 and IL-8] categorized for
Normal HDL-c and Low HDL-c groups are presented in Table 4. None of the inflammatory
markers were significantly different between groups. There was a negative correlation between
HDL-c and ALT, which is one of the liver enzymes as shown in Figure 19.
Table 4. Inflammatory markers and liver enzymes in Normal HDL-c and Low HDL-c groups
Parameter

Normal HDL-c

Low HDL-c

P value

AST (U/L)
ALT (U/L)

25.0 ± 6.1
29.2 ± 10.7

26.2 ± 7.4
29.6 ± 10.8

0.598
0.915

CRP (mg/dL)

0.39 ± 0.39

0.31 ± 0.29

0.456

TNF- (pg/mL)

6.2 ± 2.4

6.9 ± 3.9

0.508

MCP-1 (pg/mL)

129.6 ± 66.6

122.2 ± 29.0

0.676

IL-6 (pg/mL)

5.5 ± 0.78

5.99 ± 1.3

0.185

IL-8 (pg/mL)

9.7 ± 10.3

7.9 ± 1.2

0.479

- Data presented as Mean ± SD
Figure 19. Negative correlation between HDL-c and ALT
r = - 0.324; p < 0.05
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4.6 Antioxidants and Oxidative Stress Biomarkers and Oxidized LDL
Plasma antioxidant and oxidative stress biomarkers [thiobarbituric acid reactive substances
(TBARS), total antioxidant capacity (TAC), superoxide dismutase (SOD), plasma glutathione
peroxidase (GPx), catalase (CAT)] as well as Ox-LDL are presented in Table 5. Total antioxidant
capacity (TAC) was significantly higher in subjects with Normal HDL-c (p = 0.044) when
compared to subjects with Low HDL-c. Other markers were not different between groups.
Table 5. Antioxidants and oxidative stress biomarkers and oxidized LDL (Ox-LDL) in Normal
HDL-c and Low HDL-c groups
Parameter

Normal HDL-c

Low HDL-c

P value

TBARS (μM)

0.16 ± 0.03

0.14 ± 0.03

0.087

TAC (mM Trolox equivalents)

2.1 ± 1.5

1.2 ± 0.9

0.044

SOD (U/mL)

2.3 ± 1.2

1.9 ± 1.2

0.361

GPx (nmol/min/mL)

150.6 ± 23.9

141.5 ± 20.2

0.220

CAT (nmol/min/mL)

19.4 ± 11.7

17.2 ± 7.0

0.507

Ox-LDL (ng/ml)

201.2 ± 14.5

212.6 ± 62.9

0.405

- Data presented as Mean ± SD
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Chapter 5
Discussion and Conclusion

Metabolic Syndrome is a well-defined condition that increases the risk of CVD and T2D1.
We assessed data collected from 40 individuals, 11 men and 29 women classified with MetS, by
separating subjects into two categories based on HDL-c concentrations. This classification allowed
us to determine whether low HDL-c is associated with additional biomarkers of CVD such as a
high atherogenic dyslipidemia, a low grade of inflammation, and high oxidative stress biomarkers.
In addition, this classification allowed us to understand the importance of measuring HDL
functionality along with measuring plasma HDL-c to identify risk factors of CVD among
participants with MetS.
In this study we found that individuals with MetS and low HDL-c had higher TG, systolic
BP, WC, and lower total antioxidant capacity than those with normal HDL-c. We also found that
subjects with low HDL-c had a more atherogenic lipoprotein profile as assessed by higher
concentrations of large VLDL, medium VLDL and small LDL. In terms of HDL functionality, we
found that Apo A-I was positively correlated with both large HDL and total HDL particles. Also,
Apo A-I was significantly lower in Low HDL-c group. Further, we found a diminished HDL
functionality as determined by PON-1 activity.
5.1 Metabolic Syndrome Parameters
Obesity is a crucial characteristic that increases the metabolic complications among
individuals with MetS. Increases in weight and BMI are strongly associated with health issues for
example: CVD, insulin resistance, T2D, hyperlipidemia, and hypertension2. Unhealthy diets and
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physical inactivity are the common habits that accelerate obesity rate3. These two factors were
shown in the subject’s diet and exercise records as high caloric intake, high saturated fatty acids
intake, and low physical activity level. As demonstrated in this study and based on BMI categories,
all subjects in this study were either overweight or obese, and more than half of them fit the obese
categories including obese I [BMI= 30.0 – 34.9 kg/m2], obese II [BMI= 35.0 – 39.9 kg/m2]. The
main problem with obesity is fat distribution and fat deposition4. Excess adipose tissues are
associated with altering adipokines production, and that might increase the risk of insulin
resistance as well as CVD4. Particularly, visceral adiposity is strongly correlated with insulin
resistance4. Visceral adiposity can be measured through measuring the waist circumference area.
WC was the most common MetS parameter determined in this population. Palaniappan et al. have
shown that each 11 cm increase in WC is associated with an adjusted 80% increased risk of
developing MetS condition5. In addition, according to the NCEP:ATP III, abdominal obesity is
known to be an essential characteristic of MetS6. All participants in the current study met the WC
requirement, in addition to two other markers of MetS diagnosis criterion. Another marker of MetS
is high BP. The mean of systolic BP was significantly increased among Low HDL-c group.
Elevated BP is known to be one of the CVD risk factors, and it was estimated that 5 mm Hg
reduction in systolic BP would result in overall reduction of 14% in stroke mortality and 9 % in
CHD mortality4. In a study done on subjects with MetS, approximately 25.1% had high TG levels
(TG > 150 mg/dL)2. In the present study, 48% of subjects had high TG levels. Plasma TG
concentrations were significantly different between the two groups. The Low HDL-c group had
higher TG values than subjects in the Normal HDL-c group. Elevated TG values are strongly
correlated with increased risk of CVD. Insulin resistance results either from a genetic defect or
obesity, and it may lead to elevation in TG and fasting glucose levels as well as BP and reduction
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of HDL-c5, as demonstrated in this study. Elevated TG was positively correlated with insulin
levels. In addition, measuring fasting glucose in obese subjects is an important predictor for other
CVD risk factors, and it is one of the MetS parameters. Since the majority of the current subjects
fit the obese category, 48% of them had hyperglycemia that placed them in MetS condition. Since
subjects were divided into two groups based on their HDL-c values, HDL-c concentrations were
significantly different between the two groups and between genders in each group. Low HDL-c
values were always linked to be a risk factor of CVD and T2D7. Observational studies have shown
that each decrease of 1-mg/dL in HDL-c concentration is associated with a 2% - 3% increased risk
of CVD8,9. In contrast, normal HDL-c concentrations are recommended and linked to be a
protective parameter against diseases.
5.2 Lipoprotein Particles
Recently, interest has shifted from not only focusing on the quantity of HDL particles but
also focusing on HDL quality9. HDL exhibits antiatherogenic mechanisms including its role in the
RCT process, anti-inflammatory, antioxidant and antithrombotic functions, all of which could
contribute to the protection against atherosclerosis10. These functions may be disrupted when HDL
particles become dysfunctional. Therefore, measuring lipoprotein particle size and number is an
important aspect to better understand lipoproteins metabolism11. Lipoproteins particles that are
considered atherogenic for example: large VLDL, medium VLDL, and small LDL particles are
present in increased numbers in the MetS populations12. The number of these particles has been
shown to be positively associated with CVD risk. In the current study, NMR method was used to
measure number and size of different lipoprotein particles. This method not only quantifies the
overall lipoprotein particles, but also measures different sizes for each lipoprotein. The NMR
method is well known as a useful and accurate method that helps to link specific lipoproteins to
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CVD11. Our findings indicate that MetS subjects with Low HDL-c had significantly increased
numbers of large and medium VLDL as well as of small LDL compared to subjects with Normal
HDL-c while large LDL particles were lower in numbers compared with the Normal HDL-c group.
Large LDL particles are known to be less susceptible to oxidation and subendothelial retention
than small LDL particles13. Calculating LDL-c did not give us enough information about the whole
picture of the LDL particles. Thus, measuring LDL particles subfractions provided important
information in regards to which particles were dominant as well as it allowed us to compare these
particles across subjects with MetS based on the HDL-c values. That also allowed us to draw a
conclusion that low HDL-c is associated with more atherogenic lipoprotein profiles. In contrast,
large HDL particles were significantly higher among subjects in the Normal HDL-c group also
indicating a more efficient RCT in this group and in addition negative correlation have been found
between HDL particles numbers and CVD14.
5.3 Apolipoproteins
In regards to apolipoproteins, Apo A-I was significantly higher in the Normal HDL-c group
compared to the Low HDL-c group. Apo A-I is mainly present in HDL particles and higher levels
of this apolipoprotein were inversely associated with CVD risk. According to the current data,
there was a positive correlation between Apo A-I and both large HDL and total HDL. Also, an
inverse correlation was found between WC and apo A-I. As mentioned previously, obesity
particularly the increase in WC, has effects on well-being, and is considered an independent risk
factor for CVD. HDL-c has been shown to improve through weight loss including decreases in
WC15. Our findings indicate that when WC increased apo A-I was decreased suggesting that HDL
might improve with decreases in weight and WC. Even though subjects in the Normal HDL-c
group has higher values of HDL-c, that does not necessary means the presence of functional HDL
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particles. Thus, measuring HDL functionality markers are important to provide a better view of
the atheroprotective lipoprotein HDL. HDL particles may have proatherogenic modifications that
lead to increase the risk of chronic diseases instead of being protective. Dysfunctional HDL result
in decreases in cholesterol efflux and increases in inflammation and thrombosis. There are some
markers indicative of HDL dysfunctionality, such as, apo C-III and SAA1. In the current study,
apo C-III was positively correlated with TG levels. It is known that apo C-III has proinflammatory
and prothrombotic effects9. HDL functionality can be evaluated through measuring apo A-I, and
PON-1. In the current study, Apo A-I was significantly lower in the Low HDL-c group in
compared to the Normal HDL-c group.
5.4 HDL Functionality [PON-1 and SAA1]
The enzyme that associates with HDL particles and has atheroprotective functions is PON1. Lower PON-1 activity is related to CHD, and the MetS condition has been shown to reduce the
enzymatic capacity of PON-116. In the current study, plasma PON-1 was measured in kinetic mode
by fluorometric assay kit. Subjects with Normal HDL-c had significantly higher PON-1 activity
compared to subjects with Low HDL-c. Increased PON-1 activity is a marker for HDL
functionality, and Normal HDL-c group had higher numbers of large HDL particles and HDL-c
concentrations. In addition, PON-1 activity levels were positively correlated with total HDL, and
with large HDL particles. Thus, large HDL particles seem to be functional in Normal HDL-c
group. One study has shown that PON-1 activity levels are significantly lower in MetS subjects16.
That finding was also demonstrated in the present study.
Another marker for HDL functionality is SAA1. SAA1 is an apolipoprotein of HDL in the
acute-phase, which causes HDL remodeling and dysfunctionality17. It was documented that SAA1
plays a major role in lipid metabolism because it can alter the distribution of cholesterol in the
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lipoproteins, and can be act as a lipid acceptor for ABCA1 but its impact on lipid metabolism
remains incompletely understood17. SAA1 for this study was measured in plasma samples, and
there was no statically difference for SAA1 between the two groups. SAA1 increases in acute
phases, and we found that SAA1 values were positively correlated with the inflammatory marker
CRP. It is well established that elevated CRP levels are associated with the increase of WC, BMI
and hyperlipidemia along with MetS condition4. That was also documented in the current study.
5.5 Inflammatory and Antioxidants Biomarkers
Individuals with MetS are often obese, and obesity is known to be associated with lowgrade inflammation and increased oxidative stress
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. Studies have shown that MetS has

independently linked with low-grads inflammation and increased oxidative stress biomarkers.
Also, plasma TNF- is positively associated with body weight, WC, and TG, while it is negatively
associated with HDL-c4. Liver enzymes are commonly used as indicators for liver functions.
Studies have shown that individuals with MetS have higher values of liver enzymes [ALT and
AST] compared with healthy populations19. Our findings indicate that HDL-c values in this
population were negatively associated with the liver enzyme ALT. While there was no significant
difference in inflammatory markers between groups, total antioxidant capacity was significantly
different. Because antioxidants are mostly carried in the body through HDL, the increase of HDL
will help in the transportation of these antioxidants throughout the body as, was demonstrated in
this study. TAC values for our subjects were significantly higher among subjects in the Normal
HDL-c group. On the other hand, lipid peroxidation markers such as Ox-LDL are increased in
MetS20. Both lipid peroxidation markers when they are at high levels, are significantly correlated
with CVD in subjects with MetS20.
5.6 Conclusions
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These data suggest that in these men and women with MetS, measuring both HDL-c
concentrations and HDL particles can provide important information about levels and functionality
of the protective HDL. In regards to plasma HDL-c, subjects with Low HDL-c appear to have
higher risk for biomarkers associated with CVD such as, high TG levels, systolic BP, and WC and
lower antioxidant capacity than subjects with Normal HDL-c. We measured lipoproteins size and
number and we found that large and medium VLDL and small LDL particles were higher in Low
HDL-c group compared with Normal HDL-c group. In contrast, large LDL, which is the one
known to be less atherogenic compared to small LDL, was significantly higher in Normal HDL-c
group. For that, it appears that in the MetS condition, having normal HDL-c concentrations, the
most common atherogenic sizes of lipoproteins are lower compared to subjects with Low HDL-c.
Apo A-I was positively correlated with total HDL and large HDL particles. In addition, we were
able to measure HDL functionality through measuring PON-1. PON-1 was positively correlated
with total HDL but there was no correlation found between PON-1 and large HDL particles, that
might due to the fact that we did not have enough subjects to find significance.
5.7 Limitations and Future Directions
In the current study, we were able to measure both HDL-c and HDL particles in 40 subjects
with MetS. Measuring both of these parameters can provide more information about the
importance and possible relationships with increased CVD risk factors. There were 11 men and 29
women in this study. For that, one possible limitation can be the unequal numbers of each gender,
which limits further analysis to be done based on gender type. Another limitation could be the
overall number of subjects in each group based on HDL-c concentrations, and this might be one
possible reason that many markers were not statistically significant. We were able to measure
inflammatory markers such as, TNF- CRP, and IL-6 that are used to determine the inflammatory
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levels as well as T2D and CVD risk factors. However, we did not measure leptin, which is an
adipokine that is involved in the regulation of satiety and energy intake4. Development of obesity
can cause increased levels of plasma leptin. Leptin is positively correlated with adiposity that can
cause leptin resistance, which is common in obese and MetS indivduals4. Also, elevated plasma
leptin levels not only affect satiety and metabolism but also have an effect on BP and increase the
peripheral vascular resistance, for hyperleptinemia, which is considered an independent CVD risk
factor4. Another important marker that we did not measure is adiponectin. Adiponectin is
negatively associated with WC, TG, fasting insulin, and blood pressure. Further, adiponectin is
positively associated with HDL in which it can enhance PON1 production4. Thus, it will be
interesting to look to these markers and to check different possible correlations in subjects with
MetS. Also, adiponectin expression is reduced by the increase of TNF-. Since individuals with
MetS have increased inflammatory markers and possibly high TG, BP and low HDL-c
concentrations, measuring adiponectin will provide interesting information in this high-risk group.
Another important point as a future direction is to assess expression for oxidative stress and
inflammation related genes in Normal HDL-c groups and Low HDL-c group. One of the
limitations of the fluorometric kit used for PON-1 measurement is requires EDTA containing tube.
Thus, we faced a technical issue during this measurement. This is one limitation that can be a
considered for future studies. It would be useful to utilize another kit such as ELISA and/or using
serum PON-1 to measure all PON-1 isoforms to better understand HDL functionality. Another
future direction is to look at gender and ethnicity as it relates to MetS, HDL-c, and HDL particles
in the data analysis. It has been indicated that gender and certain ethnicities can be different in
regards MetS parameters and HDL functionality. Therefore, it will be interesting to examine these
factors and how they are different between groups.
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